|

The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

RECRUITINGN/ASponsored by Jules Bordet Institute
Actively Recruiting
PhaseN/A
SponsorJules Bordet Institute
Started2025-05-09
Est. completion2027-12
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07109440

Summary

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age above 18 years.
* Liver metastasis on standard imaging for the initial assessment (MRI, FDG PET/CT)
* Naïve for treatment or after neoadjuvant chemotherapy
* Scheduled for liver metastasis resection
* ECOG Performance status ≤2.
* Signed written informed consent

Exclusion Criteria:

* Non-resectable liver metastases
* Pregnant and lactating women
* Subjects with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.

Conditions3

CancerLiver CancerLiver Metastases From Colorectal Cancer

Browse More Trials

Cancer trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.